AI-generated research brief — verify at source
MUSKARDIA Cuts MACE Risk by Half in CAD Patients with Lower Hemoglobin
In CAD patients with baseline hemoglobin below 140 g/L, MUSKARDIA (Shexiang Baoxin Pill) was associated with roughly half the risk of major adverse cardiovascular events compared to placebo — about 55% lower risk (HR 0.45, 95% CI 0.21–0.96, P=0.038) — along with a 68% reduction in non-fatal myocardial infarction. No comparable benefit was observed in patients with hemoglobin above 140 g/L, suggesting that hemoglobin level may meaningfully modify treatment response.
What Was Studied
This analysis examined whether the cardiovascular benefit of MUSKARDIA, a traditional Chinese medicine formulation, differs according to patients’ baseline hemoglobin levels. The primary outcome of interest was the incidence of major adverse cardiovascular events (MACE), with secondary attention to non-fatal myocardial infarction, non-fatal stroke, and all-cause mortality in patients with chronic stable coronary artery disease.
How It Was Studied
This work is a pre-specified secondary subgroup analysis drawn from a multicenter, randomized, double-blind, placebo-controlled phase IV trial enrolling 2,494 adults with chronic stable coronary artery disease. Patients were stratified by baseline hemoglobin into two groups: Group A (Hb < 140 g/L, n=1,286) and Group B (Hb > 140 g/L, n=1,208). Within each stratum, participants received either MUSKARDIA or matched placebo. The effect of treatment on time-to-event outcomes was modeled using Cox proportional hazards regression, yielding hazard ratios with 95% confidence intervals for each subgroup.
What Was Observed
- MACE reduction in the lower-hemoglobin group: Among patients with Hb < 140 g/L, MUSKARDIA was associated with approximately 55% lower risk of MACE compared to placebo (HR 0.45, 95% CI 0.21–0.96, P=0.038). This represents a statistically significant finding in this subgroup, though the wide confidence interval reflects meaningful uncertainty around the point estimate.
- Non-fatal MI reduction in Group A: Within the same lower-hemoglobin subgroup, MUSKARDIA was associated with a 68% reduction in the risk of non-fatal myocardial infarction (P=0.036). No statistically significant differences were observed for non-fatal stroke or all-cause mortality in this group.
- Absence of benefit in the higher-hemoglobin group: Among patients with Hb > 140 g/L, MUSKARDIA showed no statistically significant reduction in MACE risk (P=0.354). There was also a numerically concerning trend toward increased non-fatal MI risk in this group (HR 1.88), though this finding was not reported as statistically significant and should be interpreted cautiously.
- Adverse event profile: In Group A, the rate of adverse events was modestly lower in the MUSKARDIA arm than in the placebo arm (15.9% vs. 17.6%). In Group B, the pattern reversed slightly, with a marginally higher rate in the MUSKARDIA arm (21.2% vs. 18.3%), though the clinical significance of these differences is not established from the reported data alone.
Why This Matters
The findings suggest that hemoglobin level may serve as a clinically meaningful modifier of MUSKARDIA’s cardiovascular efficacy, with patients characterized by lower hemoglobin — and therefore presumably greater ischemic risk due to reduced myocardial oxygen delivery — appearing to derive the most benefit. This pattern supports the hypothesis that MUSKARDIA’s cardiovascular protective effects may be most relevant in populations with physiologically compromised oxygen supply to the heart. The differential response across hemoglobin strata underscores the potential value of biomarker-stratified approaches when evaluating integrative cardiovascular therapies.
How to Read This Result
While the trial design is rigorous, this is a secondary subgroup analysis with a wide confidence interval around the primary effect estimate, raising the possibility of chance findings due to multiple comparisons and limiting the strength of any causal inference that can be drawn.
Limitations
The abstract does not explicitly report study limitations.